About

ELEVATE-DP is a five-year study (with a one year no-cost extension) funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the Nationate Institute of Health (NIH) under Award Number R18DK110739. The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Background

  • DPP Trial (1996-1999): 27-center RCT of a behavioral lifestyle intervention vs. metformin vs. placebo in individuals with high risk for type 2 diabetes
    • First to show that behavioral modification is more effective than medication for diabetes prevention (58% and 31% reduced risk vs. placebo)
  • Primary mechanism of diabetes prevention was weight loss with each kg of weight loss corresponding to a 16% reduced risk of diabetes
  • Subsequently, group-based adaptations of the DPP intervention were implemented in community settings (YMCAs, churches, worksites)
  • Although LCPs hold much promise, attempts to evaluate the effectiveness of DPP adaptations within real-world settings rather than in research settings have been limited.

Goal of Study

  • To examine the implementation and effectiveness of a behavioral lifestyle intervention for weight loss and diabetes prevention in a healthcare delivery system

From left to right: [top row] Kristen Azar, Robert Romanelli, Sylvia Sudat, Vidita Chopra, Catherine Nasrallah, Jack Petersen. [bottom row] Alice Pressman, Meghan Halley, Nina Szwerinski, Claire Huang